12:00 AM
 | 
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EndoBarrier Gastrointestinal Liner: Additional pilot trial data

Additional data from an open-label pilot trial in 19 evaluable patients showed that EndoBarrier Gastrointestinal Liner reduced HbA1c and mean fasting plasma glucose (FPG) by 1.5% and 16.3 mg/dL, respectively, from 7.8% and 141.1 mg/dL at baseline to...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >